Executive Summary
MIF1, MIF2, Ac-MIF1, Ac-MIF2, MIF1-NH2, MIF2-NH2, Ac-MIF1-NH2, and Ac-MIF2-NH2 by K Takayama·2022·Cited by 14—Myostatin(growth differentiation factor-8, GDF-8), a member of the transforming growth factor-β (TGF-β) superfamily, suppresses the growth of
The quest for enhanced muscle growth and therapeutic interventions for muscle-wasting conditions has led to significant research into myostatin inhibitors. Myostatin, also known as growth differentiation factor 8 (GDF-8), is a protein that plays a crucial role in regulating muscle development. By inhibiting the action of myostatin, the goal is to unlock the body's potential for increased muscle mass and strength. This article delves into the various myostatin inhibitor peptide names that have emerged from scientific inquiry, providing a comprehensive overview of these compounds and their potential applications.
At the forefront of this research are specific peptide sequences designed to block the activity of myostatin. These peptides are often derived from naturally occurring proteins or are synthetically engineered to interact with myostatin or its signaling pathways. Among the notable myostatin inhibitor peptide names are MIF1 and MIF2, along with their modified forms: Ac-MIF1, Ac-MIF2, MIF1-NH2, MIF2-NH2, Ac-MIF1-NH2, and Ac-MIF2-NH2. These peptides were identified through in silico studies and subsequently synthesized, demonstrating their potential as potent muscle growth promoters.
Another significant area of investigation involves peptides derived from follistatin. Follistatin itself is a known myostatin antagonist, and researchers have explored follistatin-derived peptides for their inhibitory capabilities. This line of research has yielded compounds that effectively inhibit myostatin, offering a novel approach to muscle enhancement.
Furthermore, specific peptides have been developed and characterized for their myostatin-inhibiting properties. Myostatin inhibitory peptide 7 TFA, for instance, is a 23-amino acid peptide originating from the mouse myostatin prodomain. Similarly, Myostatin inhibitory peptide 2 (compd 2) TFA has been identified with a dissociation constant (Kd) of 35.9 nM, indicating a strong binding affinity for its target. The development of chain-shortened myostatin inhibitory peptide 8a (MIPE-1686) also represents progress, showing promise for drug development in treating muscle atrophic disorders. Another notable peptide is myostatin inhibitory peptide 3d, which displayed a potent IC50 value of 0.32 μM.
Beyond these specific peptide names, the broader category of myostatin inhibitors encompasses a range of molecules. Myostatin inhibitors are a type of drug that target myostatin, and this includes not only peptides but also antibodies and other small molecules. For example, YK-11 is recognized as a selective androgen receptor modulator with myostatin inhibitory effects. ACE-031 has been investigated for its therapeutic potential in conditions like Duchenne muscular dystrophy. In the realm of natural compounds, Epicatechin, found in dark chocolate and green tea, is also considered a potent myostatin inhibitor. Clinical trials have explored the efficacy of myostatin inhibitors like bimagrumab in obesity studies, showing significant reductions in body weight.
The scientific literature also mentions specific research platforms and compounds aimed at myostatin blockade. The GDF8 / Myostatin Blocking Peptide is a commercially available reagent for research purposes. The MYOSTATIN INHIBITION PLATFORM represents broader research initiatives, including studies evaluating the efficacy and safety of drugs like Taldefgrobep Alfa in conditions such as spinal muscular atrophy. Other identified myostatin inhibitors include LY2495655 and MYO-029, which are often Myostatin antibodies.
It is important to note that the development of these compounds is an ongoing scientific endeavor. Research into myostatin and its inhibitors is driven by the desire to understand its role in muscle homeostasis and to develop therapeutic strategies for various diseases. The precise mechanisms by which these peptides exert their effects, such as their binding affinities and the specific amino acid regions they target – like the synthetic peptide taken within amino acid region 325-375 on human Myostatin – are subjects of continued investigation. The ultimate goal is to leverage these scientific advancements to promote muscle growth and combat muscle loss effectively and safely.
Related Articles
Frequently Asked Questions
Here are the most common questions about .
Leave a Comment
Share your thoughts, feedback, or additional insights on this topic.
